Morningstar Investor users sign in here.

Anna Baran

Anna Baran

 is an equity analyst for Morningstar

BioNTech, Pfizer report good news from vaccine trial
Stocks
BioNTech, Pfizer report good news from vaccine trial
A long road lies ahead as the trial continues, but we are maintaining our fair value estimates for the two healthcare firms, says Morningstar’s...